BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Earnings of -$0.28 Per Share

Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post earnings per share (EPS) of ($0.28) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.25). BioCryst Pharmaceuticals reported earnings per share of ($0.26) during the same quarter last year, which would indicate a negative year-over-year growth rate of 7.7%. The company is expected to issue its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($1.09). For the next financial year, analysts expect that the business will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.35) to ($0.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $2.39 million. BioCryst Pharmaceuticals had a negative return on equity of 175.83% and a negative net margin of 490.25%.

Several research firms recently commented on BCRX. Zacks Investment Research raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 26th. Barclays increased their target price on BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, April 2nd. BidaskClub lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. Finally, JMP Securities increased their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company a “market outperform” rating in a report on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.91.

In other BioCryst Pharmaceuticals news, VP Lynne Powell sold 12,000 shares of the firm’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $9.75, for a total transaction of $117,000.00. Following the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at $58,500. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Thomas R. Staab II sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $9.85, for a total value of $49,250.00. Following the transaction, the chief financial officer now directly owns 133,426 shares in the company, valued at approximately $1,314,246.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,546 shares of company stock worth $336,961. Corporate insiders own 4.50% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Paloma Partners Management Co acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $84,000. Amalgamated Bank acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $122,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth about $122,000. Legal & General Group Plc boosted its stake in shares of BioCryst Pharmaceuticals by 14.5% during the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after buying an additional 2,453 shares during the period. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $232,000. 91.90% of the stock is currently owned by institutional investors.

NASDAQ:BCRX opened at $8.53 on Friday. The firm has a market capitalization of $965.15 million, a P/E ratio of -8.70 and a beta of 1.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.62 and a current ratio of 1.65. BioCryst Pharmaceuticals has a 12 month low of $4.76 and a 12 month high of $9.95.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Story: What is a stock buyback?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.